REV-ERB agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-13. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | SR9009; Stenabolic | Nickname is not a chemical name. |
| Typical analytical method | LC-MS/MS | Often with isotope-labeled internal standard. |
| Storage temperature | -20 °C | Desiccated and protected from light. |
| Solution stability | DMSO stock; avoid freeze-thaw | Store at -20 to -80 °C. |
| Regulatory status | Not approved; varies by country | May be restricted as research chemical. |
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
=== Food packaging === A good food packaging material should be able to block out microbes (to prevent spoiling and foodborne illness) and prevent oxygen from entering (to prevent rancidity). Depending on the product, it may be also desirable to stop water vapor from going across (to maintain crispness or wetness), to block out light and ultraviolet, and/or be resistant to rough handling. Classical plastic-based materials satisfy these criteria, but they are not biodegradable and create a trash problem. Among biodegradable options, chitosan films and chitosan composite films come closest to fulfilling all of these goals. Chitosan also has an intrinsic antimicrobial activity, which could potentially provide an extra line of defense to microbes.
== Function == The protein is a pyrimidine catabolic enzyme and the initial and rate-limiting factor in the pathway of uracil and thymidine catabolism. Genetic deficiency of this enzyme results in an error in pyrimidine metabolism associated with thymine-uraciluria and an increased risk of toxicity in cancer patients receiving 5-fluorouracil chemotherapy.
Ancient pyramidical structures, mausoleums, ruined cities and stone walls, such as the Wargaade Wall, are evidence of an old civilisation that once thrived in the Somali peninsula. This civilisation enjoyed a trading relationship with ancient Egypt and Mycenaean Greece since the second millennium BC, supporting the hypothesis that Somalia or adjacent regions were the location of the ancient Land of Punt. The Puntites native to the region traded myrrh, spices, gold, ebony, short-horned cattle, ivory and frankincense with the Egyptians, Phoenicians, Babylonians, Indians, Chinese and Romans through their commercial ports. An Egyptian expedition sent to Punt by the 18th dynasty Queen Hatshepsut is recorded on the temple reliefs at Deir el-Bahari, during the reign of the Puntite King Parahu and Queen Ati. In the classical era, the Macrobians, who may have been ancestral to Somalis, established a powerful kingdom that ruled large parts of modern Somalia. They were reputed for their longevity and wealth, and were said to be the "tallest and handsomest of all men". The Macrobians were warrior herders and seafarers. According to Herodotus' account, the Persian Emperor Cambyses II, upon his conquest of Egypt in 525 BC, sent ambassadors to Macrobia, bringing luxury gifts for the Macrobian king to entice his submission.
The coenzyme NAD+ was first discovered by the British biochemists Arthur Harden and William John Young in 1906. They noticed that adding boiled and filtered yeast extract greatly accelerated alcoholic fermentation in unboiled yeast extracts. They called the unidentified factor responsible for this effect a coferment. Through a long and difficult purification from yeast extracts, this heat-stable factor was identified as a nucleotide sugar phosphate by Hans von Euler-Chelpin. In 1936, the German scientist Otto Heinrich Warburg showed the function of the nucleotide coenzyme in hydride transfer and identified the nicotinamide portion as the site of redox reactions. Vitamin precursors of NAD+ were first identified in 1938, when Conrad Elvehjem showed that liver has an "anti-black tongue" activity in the form of nicotinamide. Then, in 1939, he provided the first strong evidence that nicotinic acid is used to synthesize NAD+. In the early 1940s, Arthur Kornberg was the first to detect an enzyme in the biosynthetic pathway. In 1949, the American biochemists Morris Friedkin and Albert L. Lehninger proved that NADH linked metabolic pathways such as the citric acid cycle with the synthesis of ATP in oxidative phosphorylation. In 1958, Jack Preiss and Philip Handler discovered the intermediates and enzymes involved in the biosynthesis of NAD+; salvage synthesis from nicotinic acid is termed the Preiss-Handler pathway. In 2004, Charles Brenner and co-workers uncovered the nicotinamide riboside kinase pathway to NAD+. The non-redox roles of NAD(P) were discovered later.
Sources: en.wikipedia.org
With scores greater or equal to 1.0 or 100%, the concept of "limiting amino acid" technically still applies as the amino acid with the lowest ratio compared to the amounts in the reference protein. It is hardly relevant, however, so such columns are parenthesized. PD is determined per PDCAAS ("true fecal") unless otherwise stated. AAS explicitly does not take into account digestibility. It compares the amino acid profile to a reference profile, which is the PDCAAS profile unless otherwise stated. Limiting AA may be determined by either PDCAAS (or a similar profile-only method) or the DIAAS (which gives the limiting absorbed AA). If unstated it is more likely to be PDCAAS. PDCAAS values are officially capped, but the limit can be removed by manually calculating PD × AAS. Examples of 5 uncapped values are seen in Schaafsma (2000).
To incorporate the effect of adhesion in Hertzian contact, Johnson, Kendall, and Roberts formulated the JKR theory of adhesive contact using a balance between the stored elastic energy and the loss in surface energy. The JKR model considers the effect of contact pressure and adhesion only inside the area of contact. The general solution for the pressure distribution in the contact area in the JKR model is
=== Booster preparations === The Atlas booster used for MA-9 sported several technical improvements, most notably an enhanced propulsion system with a hypergolic igniter that would eliminate the need for hold-down time at launch to prevent rough combustion. With seven successful Mercury launches in a row, the failures of the early days seemed like a distant memory by early 1963 and NASA officials had a high degree of confidence in the Atlas that overshadowed its still spotty launch record. At the first meeting of senior MSFC officials for the year (January 11), Walter Williams noted that the Air Force had yet to provide an explanation for two Atlas F failures during the second half of 1962. Until the investigation committees released their findings and cleared the Atlas D of guilt by association, Cooper's flight could be delayed. During the seven months between Schirra's and Cooper's flights, there were five failures of Atlas D vehicles (one of them an Atlas-Agena, the rest operational ICBM tests). NASA did not let its guard down on the Atlas, despite the recent high degree of success enjoyed by Project Mercury. When Atlas 130D received its factory rollout on January 30, it was found to have damaged wiring and had to be sent back for repairs. At his first press conference on February 8, Gordon Cooper admitted to not knowing much about the booster problems and focused instead on the enhancements made to his Mercury capsule.
Sources: en.wikipedia.org
=== War in Yemen (2014–present) === Yemen was riven in 2015, with the Houthis establishing a new government in Sanaa and Hadi retreating with his supporters to Aden, and later Saudi Arabia. The Arab League, led by the Saudis, began a bombing campaign and mobilization of various armed forces in the region for a possible invasion.
Bruce Malcolm Reid (4 April 1946 – 27 October 2020) was an Australian doctor and former Australian rules footballer. He was the senior medical officer at the Essendon Football Club and played for Hawthorn in the Victorian Football League (VFL).
Antibody–drug conjugates or ADCs are a class of bioconjugates and immunoconjugates. ADCs are composed of an antibody linked to a cytotoxic (anticancer) "payload" or drug. Among treatment options for cancer, chemotherapy is most widely used. Its main limitation is low target specificity. Unlike chemotherapy, ADCs target tumor cells while sparing healthy cells. As of 2019, some 56 pharmaceutical companies were developing ADCs. ADCs combine the targeting properties of monoclonal antibodies with the cancer-killing capabilities of cytotoxic drugs, designed to discriminate between healthy and diseased tissue.
Sources: en.wikipedia.org
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.
Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.
Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.